| pubmed-article:10404320 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10404320 | lifeskim:mentions | umls-concept:C0155862 | lld:lifeskim |
| pubmed-article:10404320 | lifeskim:mentions | umls-concept:C1522424 | lld:lifeskim |
| pubmed-article:10404320 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:10404320 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
| pubmed-article:10404320 | lifeskim:mentions | umls-concept:C0379881 | lld:lifeskim |
| pubmed-article:10404320 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10404320 | pubmed:dateCreated | 1999-9-30 | lld:pubmed |
| pubmed-article:10404320 | pubmed:abstractText | Trovafloxacin is a potentially useful agent for treatment of infections caused by cephalosporin-resistant Streptococcus pneumoniae. We studied the effectiveness of trovafloxacin therapy and examined the correlation between pharmacodynamic indices in serum and lung, and bacterial killing. Immunocompetent Balb/c mice were infected by intranasal inoculation of a cephalosporin-resistant S. pneumoniae isolate (MIC of ceftriaxone and trovafloxacin 2 and 0.06 mg/L, respectively). Trovafloxacin 10-30 mg/kg/day in one or three divided doses was started 15 h after infection. Serum and lung drug concentrations were measured at multiple time points for 24 h. Serum concentrations peaked at 30-60 min and lung concentrations approximately 30 min later. The serum T1/2 was approximately 9 h and lung T1/2 varied from 5 to 9 h. Lung AUC and Cmax values were 2-3 times greater than those in serum. At the start of therapy lung bacterial concentrations were 8.4 +/- 0.3 log10 cfu/mL and 24 h later had decreased by 3.5 +/- 0.2, 4.0 +/- 0.2, 0.8 +/- 0.3 and 1.0 +/- 1.2 log10 cfu/mL with 30 mg/kg x 1, 10 mg/kg x 3, 10 mg/kg x 1 and 3.3 mg/kg x 3 regimens, respectively. Although the larger dosages were more effective (P < 0.001) the differences between divided and single dosage regimens were not significant. Trovafloxacin serum AUC/MIC ratio correlated best with bacterial killing in the lungs over 24 h. Trovafloxacin is likely to be useful in the treatment of cephalosporin-resistant S. pneumoniae pneumonia. | lld:pubmed |
| pubmed-article:10404320 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10404320 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10404320 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10404320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10404320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10404320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10404320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10404320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10404320 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10404320 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:10404320 | pubmed:issn | 0305-7453 | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:McCrackenG... | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:OHWW | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:FriedlandI... | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:WubbelLL | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:LutsarII | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:JafriHH | lld:pubmed |
| pubmed-article:10404320 | pubmed:author | pubmed-author:GhaffarFF | lld:pubmed |
| pubmed-article:10404320 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10404320 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:10404320 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10404320 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10404320 | pubmed:pagination | 811-6 | lld:pubmed |
| pubmed-article:10404320 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:meshHeading | pubmed-meshheading:10404320... | lld:pubmed |
| pubmed-article:10404320 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10404320 | pubmed:articleTitle | Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. | lld:pubmed |
| pubmed-article:10404320 | pubmed:affiliation | University of Texas Southwestern Medical Center, Dallas 75235, USA. | lld:pubmed |
| pubmed-article:10404320 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10404320 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10404320 | lld:pubmed |
